Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Effect of cyclosporine on steady-state pharmacokinetics of MPA in renal transplant recipients is not affected by the MPA formulation: analysis based on therapeutic drug monitoring data. (CROSBI ID 211735)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Trkulja, Vladimir ; Lalić, Zdenka ; Nađ-Škegro, Sandra ; Lebo, Ana ; Granić, Paula ; Lovrić, Mila ; Pasini, Josip ; Božina, Nada Effect of cyclosporine on steady-state pharmacokinetics of MPA in renal transplant recipients is not affected by the MPA formulation: analysis based on therapeutic drug monitoring data. // Therapeutic drug monitoring, 36 (2014), 4; 456-464. doi: 10.1097/FTD.0000000000000052

Podaci o odgovornosti

Trkulja, Vladimir ; Lalić, Zdenka ; Nađ-Škegro, Sandra ; Lebo, Ana ; Granić, Paula ; Lovrić, Mila ; Pasini, Josip ; Božina, Nada

engleski

Effect of cyclosporine on steady-state pharmacokinetics of MPA in renal transplant recipients is not affected by the MPA formulation: analysis based on therapeutic drug monitoring data.

Two oral mycophenolic acid (MPA) formulations, immediate-release mycophenolate mofetil and enteric-coated mycophenolate sodium, have been shown to differ regarding some drug-drug interactions. The aim was to assess whether the effects of cyclosporine (CsA) on steady-state pharmacokinetics (PK) of MPA in renal transplant patients were affected by MPA formulation. A prospective, stratified observational study based on therapeutic drug monitoring of MPA (6 total plasma concentrations over a 12-hour dosing interval, tau) in consecutive stable adult renal transplant recipients (n = 68). Patients treated with enteric-coated mycophenolate sodium (n = 45) or mycophenolate mofetil (n = 23) and with either CsA (micro- emulsion, n = 43) or tacrolimus (Tac) (immediate release, n = 25) were comparable regarding demographics, comorbidity, renal and liver functions, comedication, corticosteroid dose, CsA or Tac dose, and trough concentrations. Based on dose-normalized MPA concentrations and with adjustment for age, sex, body mass index, estimated glomerular filtration rate, and corticosteroid dose, CsA (as compared with Tac) consistently reduced MPA area under the concentration-time curve during the dosing interval at steady state overall [geometric mean ratio (GMR), 0.78 ; 95% confidence interval, 0.62-0.99] and by MPA formulation (by 22% and 21%, respectively), increased CLT/F, ss overall (1.31 ; 1.00-1.70) and by formulation (by 25% and 36%, respectively), reduced morning predose MPA concentration overall (0.59 ; 0.38-0.92) and by formulation (by 34% and 47%, respectively), increased peak-trough fluctuation overall (1.51 ; 1.06-2.17) and by formulation (by 58% and 45%, respectively), and prolonged t(max, ss) overall (adjusted median difference 0.58, 0.04- 1.12 hours) and by formulation (by 0.6 and 0.5 hours, respectively).

mycophenolate mofetil; enteric-coated mycophenolate sodium; cyclosporine; tacrolimus; renal transplant patients; therapeutic drug monitoring

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

36 (4)

2014.

456-464

objavljeno

0163-4356

10.1097/FTD.0000000000000052

Povezanost rada

Kliničke medicinske znanosti

Poveznice
Indeksiranost